|Classification and external resources|
Peripartum cardiomyopathy (PPCM) is a form of dilated cardiomyopathy that is defined as a deterioration in cardiac function presenting typically between the last month of pregnancy and up to six months postpartum. As with other forms of dilated cardiomyopathy, PPCM involves systolic dysfunction of the heart with a decrease of the left ventricular ejection fraction (EF) with associated congestive heart failure and an increased risk of atrial and ventricular arrhythmias, thromboembolism (blockage of a blood vessel by a blood clot), and even sudden cardiac death. In essence, the heart muscle cannot contract forcefully enough to pump adequate amounts of blood for the needs of the body's vital organs.
PPCM is a diagnosis of exclusion, wherein patients have no prior history of heart disease and there are no other known possible causes of heart failure. Echocardiogram is used to both diagnose and monitor the effectiveness of treatment for PPCM.
The cause of PPCM is unknown. Currently, researchers are investigating cardiotropic viruses, autoimmunity or immune system dysfunction, other toxins that serve as triggers to immune system dysfunction, micronutrient or trace mineral definciencies, and genetics as possible components that contribute to or cause the development of PPCM.
The process of PPCM begins with an unknown trigger (possibly a cardiotropic virus or other yet unidentified catalyst) that initiates an inflammatory process in the heart. Consequently, heart muscle cells are damaged; some die or become scar tissue. Scar tissue has no ability to contract; therefore, the effectiveness of the pumping action of the heart is decreased. Also, damage to the cytoskeletal framework of the heart causes the heart to enlarge, stretch or alter in shape, also decreasing the heart's systolic function or output. The initial inflammatory process appears to cause an autoimmune or immune dysfunctional process, which in turn fuels the initial inflammatory process. Progressive loss of heart muscle cells leads to eventual heart failure.
Signs and symptoms
Symptoms usually include one or more of the following: orthopnea (difficulty breathing while lying flat), dyspnea (shortness of breath on exertion), pitting edema (swelling), cough, frequent night-time urination, excessive weight gain during the last month of pregnancy (1-2+ kg/week; two to four or more pounds per week), palpitations (sensation of racing heart-rate, skipping beats, long pauses between beats, or fluttering), and chest pain.
The shortness of breath is often described by PPCM patients as the inability to take a deep or full breath or to get enough air into the lungs. Also, patients often describe the need to prop themselves up overnight by using two or more pillows in order to breathe better. These symptoms, swelling, and/or cough may be indications of pulmonary edema (fluid in the lungs) resulting from acute heart failure and PPCM.
Unfortunately, patients and clinicians sometimes dismiss early symptoms because they appear to be typical of normal pregnancy. Yet, early detection and treatment are critically important to the patient with PPCM. Delays in diagnosis and treatment of PPCM are associated with increased morbidity and mortality.
It is important to note that occasionally patients present with other signs or symptoms. This is demonstrated by one report of a woman with liver failure five weeks postpartum who was being considered for liver transplant. An echocardiogram was performed and revealed PPCM and heart failure as the cause of her severe liver failure. Conventional heart failure medications were administered. She survived and completely recovered from both the liver failure and PPCM.
It is also quite common for women to present with evidence of having an embolus (clot) passing from the heart to a vital organ, causing such complications as stroke, loss of circulation to a limb, even coronary artery occlusion (blockage) with typical myocardial infarction (heart attack).
The following is a screening tool developed by James D. Fett, MD, which may be useful to patients and medical professionals in determining the need to take further action to diagnose symptoms:
|Focused medical history for PPCM screening, looking for early symptoms of heart failure, during last month of pregnancy:|
|1. Orthopnea (difficulty breathing while lying flat):|
|a.) None = 0 points; b.) Need to elevate head = 1 point; c.) Need to elevate upper body 45° or more = 2 points|
|2. Dyspnea (shortness of breath on exertion):|
|a.) None = 0 points; b.) Climbing 8 or more steps = 1 point; c.) Walking on level = 2 points|
|3. Unexplained cough:|
|a.) None = 0 points; b.) Night-time = 1 point; c.) Day and night = 2 points|
|4. Swelling (pitting edema) lower extremities:|
|a.) None = 0 points; b.) Below knee = 1 point; c.) Above and below knee and/or hands/face = 2 points.|
|5. Excessive weight gain during last month of pregnancy:|
|a.) Under 2 pounds per week = 0 points; b.) 2 to 4 pounds per week = 1 point; c.) over 4 pounds per week = 2 points.|
|6. Palpitations (sensation of irregular heart beats):|
|a.) None = 0 points; b.) When lying down at night = 1 point; c.) Day and night, any position = 2 points|
|Scoring and Action:|
|0 - 2 = low risk—continue observation|
|3 - 4 = mild risk—consider doing blood BNP and CRP; echocardiogram if BNP and CRP are elevated|
|5 or more = high risk—do blood BNP, CRP, and echocardiogram|
Treatment for PPCM is similar to treatment for congestive heart failure. Conventional heart failure treatment includes the use of diuretics, beta blockers (B-B), and angiotensin-converting enzyme inhibitors (ACE-I) after delivery. Diuretics, preferably furosemide, help the body to get rid of excess water weight and also lower blood pressure. ACE-I and B-B improve blood circulation and contribute to the reversal of the immune system dysfunction associated with PPCM. If ACE-I is not well tolerated by the patient, it can be replaced by angiotensin receptor blockers (ARB). Hydralazine with nitrates may replace ACE-I in breastfeeding mothers or before delivery; however, evidence suggests that this course of treatment may not be as effective as ACE-I but beneficial when necessary.
If EF is less than 35%, anticoagulation is indicated, as there is a greater risk of developing left ventricular thrombi (blood clots). Sometimes implantation of a left ventricular assist device (LVAD) or even heart transplant also becomes necessary.
It is important that the patient receives regular follow-up care including frequent echocardiograms to monitor improvement or the lack thereof, particularly after changes of medical treatment regimes.
Patients who do not respond to initial treatment, defined as left ventricular EF remaining below 20% at two months or below 40% at three months with conventional treatment may merit further investigation, including cardiac magnetic resonance imaging (MRI), cardiac catheterization, and endomyocardial biopsy for special staining and for viral polymerase chain reaction (PCR) analysis. Antiviral therapy, immunoabsorption, intravenous gamma globulin, or other immunomodulation therapy may then be considered accordingly, but following a controlled research-type protocol.
Since no one knows for sure exactly when to discontinue treatment, even when recovery occurs quickly, it is still recommended that both ACE-I and B-B be continued for at least one year after diagnosis.
The most recent studies indicate that with newer conventional heart failure treatment consisting of diuretics, ACE inhibitors and beta blockers, the survival rate is very high at 98% or better, and almost all PPCM patients improve with treatment. In the United States, over 50% of PPCM patients experience complete recovery of heart function (EF 55% or greater). Almost all recovered patients are eventually able to discontinue medications with no resulting relapse and have normal life expectancy.
It is a misconception that hope for recovery depends upon improvement or recovery within the first six to 12 months of diagnosis. Many women continue to improve or recover even years after diagnosis with continued medicinal treatment. Once fully recovered, if there is no subsequent pregnancy, the possibility of relapse or recurrence of heart failure is minimal.
Subsequent pregnancy should be avoided when left ventricular function has not recovered and the EF is lower than 55%. However, many women who have fully recovered from PPCM have gone on to have successful subsequent pregnancies. A significant study reports that the risk for recurrence of heart failure in recovered PPCM patients as a result of subsequent pregnancy is approximately 21% or better. The chance of relapse may be even smaller for those with normal contractile reserve as demonstrated by stress echocardiography. In any subsequent pregnancy, careful monitoring is necessary. Where relapse occurs, conventional treatment should be resumed, including hydralazine with nitrates plus beta-blockers during pregnancy, or ACE-inhibitors plus beta-blockers following pregnancy.
It is estimated that the incidence of PPCM in the United States is between 1 in 1300 to 4000 live births. While it can affect women of all races, it is more prevalent in some countries; for example, estimates suggest that PPCM occurs at rates of one in 1000 live births in South African Bantus, and as high as one in 300 in Haiti.
Some studies assert that PPCM may be slightly more prevalent among older women who have had higher numbers of liveborn children and among women of older and younger extremes of childbearing age. However, a quarter to a third of PPCM patients are young women who have given birth for the first time.
While the use of tocolytic agents or the development of preeclampsia (toxemia of pregnancy) and pregnancy-induced hypertension (PIH) may contribute to the worsening of heart failure, they do not cause PPCM; the majority of women have developed PPCM who neither received tocolytics nor had preeclampsia nor PIH.
In short, PPCM can occur in any woman of any racial background, at any age during reproductive years, and in any pregnancy.
- Pearson GD, Veille JC, Rahimtoola S et al. (March 2000). "Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review". JAMA 283 (9): 1183–8. doi:10.1001/jama.283.9.1183. PMID 10703781.
- Elkayam U, Akhter MW, Singh H et al. (April 2005). "Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation". Circulation 111 (16): 2050–5. doi:10.1161/01.CIR.0000162478.36652.7E. PMID 15851613.
- Sliwa K, Fett J, Elkayam U (August 2006). "Peripartum cardiomyopathy". Lancet 368 (9536): 687–93. doi:10.1016/S0140-6736(06)69253-2. PMID 16920474.
- Murali S, Baldisseri MR (October 2005). "Peripartum cardiomyopathy". Crit. Care Med. 33 (10 Suppl): S340–6. doi:10.1097/01.CCM.0000183500.47273.8E. PMID 16215357.
- Phillips SD, Warnes CA (2004). "Peripartum Cardiomyopathy: Current Therapeutic Perspectives". Curr Treat Options Cardiovasc Med 6 (6): 481–488. doi:10.1007/s11936-004-0005-8. PMID 15496265.
- Ansari AA, Fett JD, Carraway RE, Mayne AE, Onlamoon N, Sundstrom JB (December 2002). "Autoimmune mechanisms as the basis for human peripartum cardiomyopathy". Clin Rev Allergy Immunol 23 (3): 301–24. doi:10.1385/CRIAI:23:3:301. PMID 12402414.
- Fett JD (October 2008). "Understanding peripartum cardiomyopathy, 2008". Int. J. Cardiol. 130 (1): 1–2. doi:10.1016/j.ijcard.2008.03.076. PMID 18590935.
- Desai D, Moodley J, Naidoo D (July 1995). "Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature". Trop Doct 25 (3): 118–23. PMID 7660481.
- Fett JD, Christie LG, Carraway RD, Ansari AA, Sundstrom JB, Murphy JG (August 2005). "Unrecognized peripartum cardiomyopathy in Haitian women". Int J Gynaecol Obstet 90 (2): 161–6. doi:10.1016/j.ijgo.2005.05.004. PMID 15961090.
- Fussell KM, Awad JA, Ware LB (April 2005). "Case of fulminant hepatic failure due to unrecognized peripartum cardiomyopathy". Crit. Care Med. 33 (4): 891–3. doi:10.1097/01.CCM.0000158517.25962.8E. PMID 15818120.
- Lasinska-Kowara M, Dudziak M, Suchorzewska J (September 2001). "Two cases of postpartum cardiomyopathy initially misdiagnosed for pulmonary embolism". Can J Anaesth 48 (8): 773–7. doi:10.1007/BF03016693. PMID 11546718.
- Fett JD (March 2011). "Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy". Critical Pathways in Cardiology (10): 44–45.
- Amos AM, Jaber WA, Russell SD (September 2006). "Improved outcomes in peripartum cardiomyopathy with contemporary treatments". Am. Heart J. 152 (3): 509–13. doi:10.1016/j.ahj.2006.02.008. PMID 16923422.
- Aziz TM, Burgess MI, Acladious NN et al. (August 1999). "Heart transplantation for peripartum cardiomyopathy: a report of three cases and a literature review". Cardiovasc Surg 7 (5): 565–7. doi:10.1016/S0967-2109(99)00014-9. PMID 10499901.
- Felker GM, Jaeger CJ, Klodas E et al. (November 2000). "Myocarditis and long-term survival in peripartum cardiomyopathy". Am. Heart J. 140 (5): 785–91. doi:10.1067/mhj.2000.110091. PMID 11054626.
- Palmer BA, Janosko KM, McTiernan C, Sherman F, McNamara DM (2007). "Left ventricular recovery in peripartum cardiomyopathy: Impact of beta-blockade (Abstract #2500)". Circulation 116 (Supplement II): 551.
- Fett JD, Christie LG, Carraway RD, Murphy JG (December 2005). "Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution" (PDF). Mayo Clin. Proc. 80 (12): 1602–6. doi:10.4065/80.12.1602. PMID 16342653.
- Elkayam U, Tummala PP, Rao K et al. (May 2001). "Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy". N. Engl. J. Med. 344 (21): 1567–71. doi:10.1056/NEJM200105243442101. PMID 11372007.
- Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM (January 1997). "Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function". Am. J. Obstet. Gynecol. 176 (1 Pt 1): 189–95. doi:10.1016/S0002-9378(97)80034-8. PMID 9024112.
- Dorbala S, Brozena S, Zeb S et al. (January 2005). "Risk stratification of women with peripartum cardiomyopathy at initial presentation: a dobutamine stress echocardiography study". J Am Soc Echocardiogr 18 (1): 45–8. doi:10.1016/j.echo.2004.08.027. PMID 15637488.
- Mielniczuk LM, Williams K, Davis DR et al. (June 2006). "Frequency of peripartum cardiomyopathy". Am. J. Cardiol. 97 (12): 1765–8. doi:10.1016/j.amjcard.2006.01.039. PMID 16765131.
- Sliwa K, Förster O, Libhaber E et al. (February 2006). "Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients". Eur. Heart J. 27 (4): 441–6. doi:10.1093/eurheartj/ehi481. PMID 16143707.
- Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P (March 2000). "Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1". J. Am. Coll. Cardiol. 35 (3): 701–5. doi:10.1016/S0735-1097(99)00624-5. PMID 10716473.